All News

RheumNow Podcast square

Count Your Telangiectasias (5.29.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and missed quiz questions.

Read Article
H2H.BKZ.RZB

BE BOLD Week 16 data - Bimekizumab vs. Risankizumab in PsA

Jack Cush, MD

UCB has released the Week 16 results from BE BOLD trial that will be presented at EULAR 2026 in London on Saturday, June 6.

Read Article
lupus.skinbx.jpg

A Role for Plasmacytoid Dendritic Cells in Lupus

Jack Cush, MD

Plasmacytoid dendritic cells (pDCs) have been strongly implicated in the pathogenesis of lupus, as their primary product, type I interferon, drive systemic lupus erythematosus and cutaneous lupus erythematosus. A recent comprehensive review synthesizes the available data on pDCs, and, importantly, what we still don't know.

Read Article
RheumNow Podcast square

Infectious Rheumatology (5.15.2026)

Jack Cush, MD

Dr. Jack Cush discusses his favorite journal articles from the past week on RheumNow.com.

Read Article
lupus.skinbx.jpg

Toll-Like Receptor Drugs Effective in Cutaneous Lupus

MedPage Today

Enpatoran, an investigational oral drug that inhibits Toll-like receptors (TLR) 7 and 8, was superior to placebo in relieving lupus skin manifestations in a dose-finding phase II trial.

Read Article
obesity.back_.jpg

Review of GLP-1 Receptor Agonists in Psoriasis

Jack Cush, MD

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed cardiometabolic medicine and are now attracting intense interest in inflammatory disorders.

Read Article
merola.aad

Litifilimab in Cutaneous Lupus Erythematosus

Jack Cush, MD

Biogen has announced positive results of their Phase 2 study, evaluating litifilimab in patients with active cutaneous lupus erythematosus (CLE), presented at the recent American Academy of Dermatology (AAD) Annual Meeting.

Read Article
RheumNow Podcast square

Top Four and More (4.10.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from RheumNow.com this week - including his top four favorite subjects.

Read Article
Retrospective Intl SSc study of MD & PT telangiectasia counts (TC) (0, 1–6, 7–15 or > 15) of face, forearms & hands. High TC correlated w/ PAH (AUC 0.824–0.875) & digital ulcers. Moderate agreement betw MD & Pt for face & forearms TC (kappa 0.648 & 0.605, p< 0.001) https://t.co/k7tVeJFeCi
Dr. John Cush RheumNow ( View Tweet)
Update on Multicentric Reticulohistiocytosis Have you ever seen multicentric reticulohistiocytosis (MRH)? Don't worry, it's a rare non-Langerhans cell histiocytosis condition characterized by papulonodular skin lesions and symmetric erosive polyarthritis, and it has only been https://t.co/koXOwktDgA
Dr. John Cush RheumNow ( View Tweet)
Parvovirus B19 Infection - Images from JAMA Dermatology. 40yoM 2-days asymptomatic rash w/ fever to 39°C, w/ arthralgias, Rash on BL cheeks, inguinal, flanks, axilla. WBC =2K, CRP 1.24 mg/dl. Dx by PCR for parvovirus B19 DNA https://t.co/LGGnabvFvA https://t.co/XzPlaWkIfz

Links:

Dr. John Cush RheumNow ( View Tweet)
Toll-Like Receptor Drugs Effective in Cutaneous Lupus Enpatoran, an investigational oral drug that inhibits Toll-like receptors (TLR) 7 and 8, was superior to placebo in relieving lupus skin manifestations in a dose-finding phase II trial. https://t.co/R1wbJHXwjD https://t.co/65HtG0Te94

Links:

Dr. John Cush RheumNow ( View Tweet)
Parvovirus B19 Infection - Images from JAMA Dermatology. 40yoM 2-days asymptomatic rash w/ fever to 39°C, w/ arthralgias, Rash on BL cheeks, inguinal, flanks, axilla. WBC =2K, CRP 1.24 mg/dl. Dx by PCR for parvovirus B19 DNA https://t.co/LGGnabvFvA https://t.co/yyBF9pEGls

Links:

Dr. John Cush RheumNow ( View Tweet)
By @RheumattDoc #Psoriasis and nail changes #PsA #PsoriaticArthritis #enthesitis #dactylitis https://t.co/rxH2zrGBwC

Links:

Dr Gurdeep S Dulay gurdeep_dulay ( View Tweet)
DERM on RheumNow PODCAST (April 2026) The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biologics, JAKs - their use, efficacy and side https://t.co/SlCGA364gj
Dr. John Cush RheumNow ( View Tweet)
Review of GLP-1 Receptor Agonists in Psoriasis Psoriasis is a chronic immune-mediated inflammatory disease plaqued by systemic comorbidities that increase morbidity, mortality, and treatment complexity. Obesity is a significant contributor to psoriatic disease. https://t.co/R1Uutdjcvz
Dr. John Cush RheumNow ( View Tweet)
Sun Pharma buys out Organon w/ $11.75 billion buyout. Both generated $6.2 billion in 2025 sales. Organon spun off from ‌Merck in 2021, specializes in women’s health and is top 7 in biosimilars. Sun is into dermatology, ophthalmology and oncology-dermatology. https://t.co/zb4hucTqCJ
Dr. John Cush RheumNow ( View Tweet)
Litifilimab in Cutaneous Lupus Erythematosus Biogen has announced positive results of their Phase 2 study, evaluating litifilimab in patients with active cutaneous lupus erythematosus (CLE), presented at the recent American Academy of Dermatology (AAD) Annual Meeting. https://t.co/3Wb6iFViOm
Dr. John Cush RheumNow ( View Tweet)
Predictors of Calcinosis Cutis in Systemic Sclerosis Calcinosis cutis (CaC) is a common and disabling non-lethal manifestation in systemic sclerosis (SSc). This study used SSc patients from the EUSTAR database to clinically characterize patients and identify risk factors for https://t.co/uXbcCa04Lv
Dr. John Cush RheumNow ( View Tweet)
Itch is common in Scleroderma (SSc) and not related to Dz duration. Study of 2173 Pts (~20K itch assessments), 87 F; mean age 55 yrs; 40% w/ diffuse SSc. Itch (moderate 4/10) seen in ~35% at all times https://t.co/QnT8d0xA5Z https://t.co/yEgB6ImDTi

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×